Skip to main content
v2026.11,986 entries · CC-BY 4.0

Medicare Advantage Prior Authorization: 42 CFR § 422.101 Rules, CMS-4201-F, AI Algorithm Guardrails & UM Committees

Technical guide to Medicare Advantage prior authorization under 42 CFR 422.101, CMS-4201-F utilization management rules, and CMS AI algorithm guardrails.

Written and maintained by CASRAI Editorial Board

Published · Last updated

On this page

Medicare Advantage prior authorization is the utilization management process governed by federal regulations at 42 CFR Part 422 under which Medicare Advantage Organizations (MAOs) evaluate the medical necessity of inpatient admissions, post-acute care stays, diagnostic procedures, and Part B therapeutics prior to service delivery. Following landmark HHS Office of Inspector General (OIG) audit findings and the promulgation of the CMS-4201-F and CMS-0057-F final rules, federal regulations strictly constrain internal coverage criteria, mandate 90-day continuity-of-care transition periods, and prohibit automated AI denials without individualized clinical review.

What Is Medicare Advantage Prior Authorization?

Under Medicare Part C, private health plans contract with the Centers for Medicare & Medicaid Services (CMS) to provide Medicare Part A and Part B benefits. While Traditional Fee-for-Service (FFS) Medicare rarely requires prior authorization, Medicare Advantage plans widely deploy prospective utilization management (prior authorization) and concurrent review to control medical expenditures. Plans and providers often use the two terms interchangeably; see precertification vs prior authorization for where the checks differ.

To prevent MA plans from erecting coverage barriers that deny beneficiaries access to care covered under Traditional Medicare, CMS codified sweeping structural protections in the Contract Year (CY) 2024 Medicare Advantage and Part D Final Rule (CMS-4201-F, 88 FR 22120) across three primary federal regulations (https://www.ecfr.gov/current/title-42/chapter-IV/subchapter-B/part-422):

  • 42 CFR § 422.101(b) and (c): Requires MAOs to abide by Traditional Medicare National Coverage Determinations (NCDs), Local Coverage Determinations (LCDs), and general Medicare coverage statutes (such as the Two-Midnight Rule at 42 CFR § 412.3) before applying any proprietary commercial criteria.
  • 42 CFR § 422.112(b)(8): Establishes continuity-of-care protections, requiring that an approved prior authorization remain valid for the full duration of the prescribed course of treatment and prohibiting disruptive mid-treatment re-authorizations.
  • 42 CFR § 422.137: Mandates that every MA plan establish a formal Utilization Management (UM) Committee led by the plan’s medical director to review and approve all prior authorization policies annually.
Federal Regulation Core Statutory Mandate Operational Impact on Payers and Providers
42 CFR § 422.101(b)(2) Mandatory adherence to Traditional Medicare statutes, NCDs, and LCDs. MA plans cannot use commercial guidelines (MCG or InterQual) to restrict or contradict explicit Medicare coverage criteria.
42 CFR § 422.101(b)(6) Limits on internal coverage criteria when Medicare coverage is not fully established. Internal criteria must be based on current evidence in widely used treatment guidelines or peer-reviewed literature and must be made publicly accessible.
42 CFR § 422.101(c)(1) Individualized medical necessity determinations. Plans must evaluate the enrollee’s specific medical history, comorbidities, physician recommendations, and local clinical notes before any denial.
42 CFR § 422.112(b)(8)(i)(B) Minimum 90-day transition period for new enrollees. During the first 90 days of enrollment, an MAO may not subject an active course of treatment to prior authorization, even if the provider is out of network.
42 CFR § 422.566(d) Qualified clinical peer review of adverse determinations. Any medical necessity denial must be reviewed by a physician or healthcare professional with appropriate clinical expertise in treating the enrollee’s condition.

CMS Medicare Advantage AI Rules and Algorithmic Guardrails

A critical focus of federal AI governance in healthcare is the use of predictive algorithms, machine learning models, and automated utilization management tools (such as post-acute length-of-stay prediction tools in skilled nursing and inpatient rehabilitation facilities). In its Contract Year 2024 Medicare Advantage Utilization Management Frequently Asked Questions (FAQs) (https://www.cms.gov/), CMS established explicit regulatory boundaries for AI in Medicare Advantage:

  1. Prohibition on Purely Algorithmic Denials: An artificial intelligence algorithm or predictive software tool cannot serve as the sole basis for denying an admission, downgrading a level of care, or terminating post-acute services. An algorithmic prediction of average length of stay based on a larger dataset does not satisfy the individualized assessment requirement of 42 CFR § 422.101(c)(1).
  2. Permitted Assistive Functions: MAOs may use AI and clinical natural language processing to assist with administrative triage—such as accelerating approvals when clinical documentation clearly satisfies an NCD/LCD, or extracting clinical entities from EHR attachments via prior authorization software.
  3. Mandatory Human-in-the-Loop Clinical Override: Before any adverse organization determination or termination of coverage is issued, a human clinician meeting the expertise standard of 42 CFR § 422.566(d) must independently examine the individual patient’s medical record, functional status, and treating physician notes.
  4. Prohibition on Shifting Criteria Post-Approval: Under 42 CFR § 422.138(c), once a Medicare Advantage plan grants prior authorization for a medically necessary item or service, it may not later deny payment on the grounds of lack of medical necessity unless there is documented fraud or material misrepresentation.

How Is Medicare Advantage Prior Authorization Used in Clinical Research and Healthcare?

In hospital revenue cycle operations, oncology trials, and health policy research, Medicare Advantage prior authorization rules intersect directly with patient access and clinical trial billing:

  • Clinical Trial Routine Costs (NCD 310.1): Under Medicare’s Clinical Trial Policy (NCD 310.1) and 42 CFR § 422.101, traditional Medicare covers the routine clinical costs of qualifying clinical trials—meaning fee-for-service Medicare Administrative Contractors (MACs) pay routine trial claims on behalf of MA enrollees when plans would otherwise impose restrictive prior authorization barriers.
  • Accelerated Decision Timelines Under CMS-0057-F: Beginning January 1, 2026 under the CMS Interoperability and Prior Authorization Final Rule (CMS-0057-F), MA plans must adjudicate expedited prior authorization requests within 72 hours and standard requests within 7 calendar days (reduced from 14 calendar days), and by January 1, 2027 must expose HL7 FHIR Prior Authorization APIs (CRD, DTR, and PAS) alongside specific denial reasons.
  • Peer-to-Peer Review and Part C Reconsiderations: When an MA plan issues an initial adverse organization determination, treating physicians utilize peer-to-peer review and formal Level 1 Plan Reconsideration appeals citing 42 CFR § 422.101(b) whenever a payer improperly substitutes internal commercial criteria for established Medicare NCDs or LCDs.

Frequently Asked Questions

What is Medicare Advantage prior authorization?

Medicare Advantage prior authorization is the prospective utilization management review conducted by private Medicare Part C health plans to verify that a requested hospital admission, diagnostic procedure, post-acute stay, or medical service meets federal coverage criteria under 42 CFR § 422.101 before care is rendered.

How is Medicare Advantage prior authorization used in clinical research and healthcare?

Healthcare providers and clinical trial teams navigate Medicare Advantage prior authorization rules—including 42 CFR § 422.101 NCD/LCD hierarchy mandates, 90-day active treatment transition protections, and CMS guardrails against algorithmic AI denials—to secure timely treatment approvals and overturn improper adverse determinations.

Follow CASRAI

Research-administration guidance, standards updates and independent tool reviews.

Ask CASRAI · free to try

Ask about Medicare Advantage Prior Authorization: 42 CFR § 422.101 Rules, CMS-4201-F, AI Algorithm Guardrails & UM Committees

2 free questions a day, no account.

An AI assistant for research: funder rules, compliance, methods and publishing. It links the sources behind its answers and labels answers that come from a web search.

Answers draw on CASRAI's guides and dictionary plus the federal and funder documents we index: Federal Register, Grants.gov, Regulations.gov and UKRI.

Works on this site and inside Claude, Cursor and the AI tools you already use.

Everything CASRAI publishes — this page, the dictionary, the guides and the news — stays open to read, with no account and no card.

Referenced across the research world

University of Cambridge logoColumbia University logoCrossref logoUniversity of Edinburgh logoHarvard University logoUniversity of Oxford logoPrinceton University logoStanford School of Medicine logoUniversity College London logoORCID logoUniversity of Cambridge logoColumbia University logoCrossref logoUniversity of Edinburgh logoHarvard University logoUniversity of Oxford logoPrinceton University logoStanford School of Medicine logoUniversity College London logoORCID logo
  • University of Cambridge logo
  • Columbia University logo
  • Crossref logo
  • University of Edinburgh logo
  • Harvard University logo
  • University of Oxford logo
  • Princeton University logo
  • Stanford School of Medicine logo
  • University College London logo
  • ORCID logo

View CASRAI adoption →